Friedrich F W, Eschenhagen T
Institut für Experimentelle und Klinische Pharmakologie und Toxikologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg.
Dtsch Med Wochenschr. 2009 Oct;134(42):2127-31. doi: 10.1055/s-0029-1241903. Epub 2009 Oct 6.
Fingolimod is a derivative of the naturally occurring immunosuppressive substance myriocin, with structural similarity to sphingosine, a ubiquitous sphingolipid. It acts as an immunomodulator interfering with the egress of T and B lymphocytes from secondary lymph organs, which results in lymphopenia. A phase II study in patients with multiple scerosis showed a significant reduction in annual relapse rate and lesions in magnetic resonance imaging with an acceptable rate of side effects. An advantage of fingolimod compared to interferon beta, glatirameracetate and natalizumab is its oral availability. Definitive assessment of the compound has to await the results of trials currently being performed.
芬戈莫德是天然存在的免疫抑制物质麦角硫因的衍生物，其结构与鞘氨醇相似，鞘氨醇是一种普遍存在的鞘脂。它作为一种免疫调节剂，干扰T和B淋巴细胞从次级淋巴器官的流出，从而导致淋巴细胞减少。一项针对多发性硬化症患者的II期研究表明，年复发率和磁共振成像中的病灶显著降低，且副作用发生率可接受。与干扰素β、醋酸格拉替雷和那他珠单抗相比，芬戈莫德的一个优点是其口服可用性。对该化合物的最终评估必须等待目前正在进行的试验结果。
